Devalla, Harsha D <br/><br/>
Atrial-like cardiomyocytes from human pluripotent stem cells are a robust preclinical model for assessing atrial-selective pharmacology.  [electronic resource] 

 -  EMBO molecular medicine  Apr 2015 
 - 394-410 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1757-4684 
<br/><br/><label>Standard No.: </label>10.15252/emmm.201404757  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Atrial Fibrillation--drug therapy<br/>Drug Delivery Systems--methods<br/>Drug Evaluation, Preclinical--methods<br/>G Protein-Coupled Inwardly-Rectifying Potassium Channels--antagonists & inhibitors<br/>Gene Expression<br/>Heart Atria--metabolism<br/>Humans<br/>Kv1.5 Potassium Channel--antagonists & inhibitors<br/>Models, Biological<br/>Myocytes, Cardiac--metabolism<br/>Pluripotent Stem Cells--metabolism<br/>Potassium Channel Blockers--pharmacology